The Accidental Blockbuster Drug
Global Popularity of Semaglutide
India’s Delayed But Decisive Entry
Patent Expiry – A Turning Point
Market Potential – $2 billion by 2030
The Competitive Landscape
Manufacturing Complexity
The Oral GLP-1 Opportunity
Conclusion
With the patent on semaglutide (a powerful diabetes & weight loss drug) ending in 2026, Indian pharma companies have a golden chance to enter a high-value market.
Top companies like Dr. Reddy’s, Cipla, Sun Pharma, Zydus, and others are planning to launch their versions by FY27. Dr. Reddy’s estimates that companies could earn healthy profit margins of 25% in this segment.
But as more players enter the market, prices are likely to fall — making it cheaper for consumers but putting pressure on those margins.
Companies entering early may enjoy strong profits for the first 1–2 years, but once competition intensifies, the benefits will quickly shrink.
